| Market Cap | 4.02M | P/E | - | EPS this Y | 98.60% | Ern Qtrly Grth | - |
| Income | -105.53M | Forward P/E | - | EPS next Y | -530.60% | 50D Avg Chg | -41.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -95.00% |
| Dividend | N/A | Price/Book | 0.02 | EPS next 5Y | - | 52W High Chg | -99.00% |
| Recommedations | 2.00 | Quick Ratio | 0.21 | Shares Outstanding | 759.49K | 52W Low Chg | 6.00% |
| Insider Own | 0.75% | ROA | -11.58% | Shares Float | 823.54K | Beta | - |
| Inst Own | 1.37% | ROE | -180.17% | Shares Shorted/Prior | 15.58K/58.06K | Price | 0.17 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 2,226,495 | Target Price | 70.00 |
| Oper. Margin | - | Earnings Date | - | Volume | 908,446 | Change | -0.18% |
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
| HC Wainwright & Co. | Buy | Mar 26, 24 |
| HC Wainwright & Co. | Buy | Mar 12, 24 |
| HC Wainwright & Co. | Buy | Feb 29, 24 |